JSR Life Sciences and its KBI Biopharma unit co-led a $10.4m round for AbSci and have picked up global marketing rights for the biomanufacturing company's forthcoming product launch.

Subsidiaries of Astellas and Novartis co-led a series B round that took Harvard's cancer treatment developer's overall funding to $60m.

Pavilion Capital and Hansjörg Wyss featured in a series B round for Harvard-founded ReadCoor, whose existing shareholders also include Lilly Asia Ventures.

Fusion Pharmaceuticals has now raised $171m altogether to deliver cancer radiopharmaceuticals based on McMaster University research.

GV and Nextech are among the participants in a series A round that is funding the launch of EQRx, which is developing cheaper copies of existing drugs.

Canada Pension Plan Investment Board has pledged up to $20m for the Varian Medical and Johnson & Johnson-backed oncology drug developer.

Eli Lilly-backed ReadCoor took its total funding to $50m and will use the funding to commercialise its gene sequencing technology.

GV-backed solid tumour treatment developer Pact Pharma has completed an oversubscribed $75m series C round led by Vida Ventures.

The payment automation software provider, which counts Mastercard and several banks among its investors, has bagged another $130m.

Proceeds from the Telstra Ventures-led series B round will allow Corvus to accelerate insurance technology development and build tools to improve its risk management.